Primary non-Hodgkin's lymphoma of the mandible treated with radiotherapy, chemotherapy, and autologous peripheral blood stem cell transplantation

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Oct;90(4):450-5. doi: 10.1067/moe.2000.108441.

Abstract

Extranodal presentation in non-Hodgkin's lymphoma (NHL) is uncommon, and the mandible is very rarely involved. Primary NHL of the mandible, for the most part, has intermediate or high malignancy and has a much greater incidence of local recurrence compared with other sites of involvement. A 48-year-old Japanese man with NHL of the mandible received radiotherapy, followed by high-dose chemotherapy supported with peripheral blood stem cell transplantation (PBSCT). High-dose cyclophosphamide, Adriamycin, and vincristine were used for pretransplant conditioning. He achieved complete remission and has survived in continuous complete remission for more than 72 months to date. Marrow-ablative chemotherapy facilitated by PBSCT is thought to be useful as part of the primary therapy for patients with NHL who have poorer prognoses.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Cranial Irradiation
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphoma, B-Cell / therapy*
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Male
  • Mandibular Neoplasms / therapy*
  • Middle Aged
  • Remission Induction